BUSINESSJun 22 · 11:45 UTCSTAT NEWSAndrew Joseph

STAT+: AbbVie to buy Apogee Therapeutics in nearly $11B deal

AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion in cash, valuing the company at $135.11 per share, a 50% premium over its previous closing price. The deal focuses on Apogee's lead drug, zumilokibart, which targets IL-13 and is being tested for inflammatory diseases like atopic dermatitis and asthma.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

AbbVieorganizationApogee TherapeuticsorganizationzumilokibarttopicIL-13topicFinancial Timesorganization

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSJun 9 · 06:48 UTC
STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
BUSINESSJun 22 · 11:48 UTC
AbbVie buys Apogee for $10.9bn to acquire inflammatory disease drug
BUSINESSApr 29 · 11:05 UTC
Chiesi Agrees to Buy KalVista Pharmaceuticals for $1.9 Billion
BUSINESSMay 22 · 06:24 UTC
GBL Backs CVC Offer to Buy Italy’s Recordati for $12 Billion
BUSINESSMay 8 · 19:29 UTC
STAT+: Roche to buy PathAI for $750 million
BUSINESSMay 7 · 08:34 UTC
STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B